vaccine

ApprovedVaccine

Pfizer

vaccine is one of 281 small molecule programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

280

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Vulvovaginal CandidiasisActive, not recruiting

LeishmaniasisActive, not recruiting

Severe Acute Respiratory SyndromeActive, not recruiting

Pancreatic CancerActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

MedulloblastomaActive, not recruiting

Acute LeukemiaActive, not recruiting

PapillomaActive, not recruiting

Respiratory Tract InfectionApproved

Active, not recruiting

Vulvovaginal CandidiasisPhase 1/Phase 2

Active, not recruiting

LeishmaniasisPhase 2

Active, not recruiting

Severe Acute Respiratory SyndromePhase 1

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

COVID-19Approved

Active, not recruiting

InfluenzaApproved

Active, not recruiting

MedulloblastomaPhase 1/Phase 2

Active, not recruiting

Acute LeukemiaPhase 1/Phase 2

Active, not recruiting

PapillomaApproved

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

vaccine

Pfizer

Approved

3 2

Bnt162b2

BioNTech

Preclinical

29 3

Stivarga

Bayer

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Singulair

AstraZeneca

Preclinical

1 6

Rayaldee

OOrganon and Co

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Statins

Sanofi

Preclinical

1 9

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 10

Olokizumab

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Vulvovaginal Candidiasis

NCT06190509

Q4 2027

Post-ApprovalNot yet recruiting

Respiratory Tract Infection

NCT06955728

Q2 2028

Post-ApprovalActive, not recruiting

Papilloma

NCT03391921

Q4 2030

Phase 2Recruiting

Pediatric Patients

NCT04948619

Clinical

Trials by Indication[1]

Influenza5 trials

Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?

Completed·MMount Sinai Hospital, Canada·Phase 4·NCT02263027·11 enrolled

Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Completed·PPT Bio Farma·Phase 2/3·NCT02093260·405 enrolled

Auto-immunity in Lupus Patients After Influenza Vaccine

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01072734·28 enrolled

Show 2 more trials

Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand

Completed·CCenters for Disease Control and Prevention·Phase 4·NCT01538940·415 enrolled

Phase 3 Trial of Serbian Seasonal Influenza Vaccine

Completed·IInstitute of Virology, Vaccines and Sera, Torlak·Phase 3·NCT02935192·480 enrolled

COVID-193 trials

Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23

Unknown status·CCenters for Disease Control and Prevention, China·Phase 4·NCT05298800·3,000 enrolled

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

Active, not recruiting·MMedicago·Phase 2/3·NCT04636697·30,918 enrolled

Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.

Completed·MMedicago·Phase 1·NCT04450004·180 enrolled

Immunogenicity2 trials

Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers

Completed·PPrince of Songkla University·Phase 1·NCT06837116·29 enrolled

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

Completed· Pfizer logo

Pfizer·Phase 2·NCT01299480·1,714 enrolled

Oral1 trial

Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00647465·140 enrolled

Allogeneic Stem Cell Transplantation1 trial

Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation

Withdrawn·UUniversity of Louisville·Phase 1·NCT01483274

15 more indications

Acute Leukemia1 trial

Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT04969601·76 enrolled

Papilloma1 trial

Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)

Active, not recruiting·—·Phase 4·NCT03391921·170 enrolled

Vulvovaginal Candidiasis1 trial

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Active, not recruiting·LLimmaTech Biologics AG·Phase 1/2·NCT06190509·251 enrolled

Vaccination1 trial

Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT07158190·30 enrolled

Flu Vaccine1 trial

Efficacy Safety Study of Flu Vaccine in Immunodepression Patients

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01022749·228 enrolled

Critical Care1 trial

Comparison of Clinical Outcome Among Vaccinated and Unvaccinated Coronavirus Disease Patients in Critical Care Unit.

Unknown status·—··NCT05331742·200 enrolled

Leishmaniasis1 trial

A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)

Withdrawn·UUniversity of York·Phase 2·NCT04107961

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04948619·64 enrolled

Experimental1 trial

A Study to Test Three Experimental HIV Vaccines in Healthy Adults.

Unknown status·UUniversity of Oxford·Phase 1·NCT04553016·88 enrolled

Pancreatic Cancer1 trial

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01896869·83 enrolled

Medulloblastoma1 trial

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

Terminated·UUniversity of Louisville·Phase 1/2·NCT02332889·1 enrolled

Advanced Solid Cancers1 trial

MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05986981·20 enrolled

Respiratory tract infection1 trial

A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.

Not yet recruiting·UUniversity of Witwatersrand, South Africa·Phase 4·NCT06955728·13,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Pfizer

vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Q4 2030

Trials by Indication[1]

Influenza5 trials

COVID-193 trials

Immunogenicity2 trials

Oral1 trial

Allogeneic Stem Cell Transplantation1 trial

Acute Leukemia1 trial

Papilloma1 trial

Vulvovaginal Candidiasis1 trial

Vaccination1 trial

Flu Vaccine1 trial

Critical Care1 trial

Leishmaniasis1 trial

Severe Acute Respiratory Syndrome1 trial

ESS1 trial

Pediatric Patients1 trial

Experimental1 trial

Pancreatic Cancer1 trial

Medulloblastoma1 trial

Advanced Solid Cancers1 trial

Respiratory tract infection1 trial

References

Drug Info

Quick Facts

Related News